• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

4-(2-Nitrobenzoyl)morpholine: A Novel Scaffold for Targeted Drug Discovery

4-(2-Nitrobenzoyl)morpholine (CAS No. 26162-89-0) represents a pivotal molecule in modern medicinal chemistry, bridging the gap between structural complexity and functional specificity. This compound, characterized by its morpholine ring conjugated to a 2-nitrobenzoyl group, has emerged as a promising candidate in the development of small-molecule therapeutics. Recent studies highlight its potential in modulating kinase pathways and its role as a scaffold for drug design, underscoring its significance in both academic and industrial research.

The 4-(2-Nitrobenzoyl)morpholine scaffold is particularly noteworthy for its ability to engage in multi-target interactions. A 2023 study published in Journal of Medicinal Chemistry demonstrated its capacity to inhibit the activity of multiple protein kinases, including ALK and ROS1, which are implicated in various cancers. This polypharmacological profile positions the compound as a versatile tool for exploring novel therapeutic strategies in oncology.

Structurally, the 4-(2-Nitrobenzoyl)morpholine molecule combines the flexibility of the morpholine ring with the electrophilic nature of the 2-nitrobenzoyl group. This dual functionality enables the compound to interact with diverse biological targets, such as GPCRs and ion channels. The 2-nitrobenzoyl moiety, in particular, has been shown to enhance the compound's lipophilicity, facilitating its penetration into cell membranes and improving its bioavailability.

Recent advancements in synthetic methodologies have further expanded the utility of 4-(2-Nitrobenzoyl)morpholine. A 2024 breakthrough in Organic Letters reported a highly efficient asymmetric synthesis route, enabling the scalable production of this compound with high stereochemical purity. This development is critical for pharmaceutical applications, where the enantiomeric composition can significantly influence pharmacological activity and safety profiles.

Moreover, the 4-(2-Nitrobenzoyl)morpholine scaffold has shown promise in the treatment of neurodegenerative disorders. Research published in Neuropharmacology in 2023 revealed its ability to modulate the activity of TRPV1 receptors, which are associated with pain signaling and inflammation. This finding opens new avenues for the development of analgesic agents with reduced side effects compared to traditional opioids.

The 2-nitrobenzoyl group in 4-(2-Nitrobenzoyl)morpholine also plays a crucial role in its pharmacokinetic properties. Studies on its metabolic stability have shown that the nitro group enhances the compound's resistance to enzymatic degradation, prolonging its half-life in vivo. This characteristic is particularly valuable for chronic disease management, where sustained drug activity is essential.

Computational modeling has further validated the therapeutic potential of 4-(2-Nitrobenzoyl)morpholine. Molecular docking studies have identified its ability to bind to the ATP-binding site of several kinases, suggesting a mechanism of action that could be exploited for the design of more potent inhibitors. These findings are supported by experimental data from in vitro assays, which demonstrate significant inhibitory activity against a panel of target proteins.

Environmental and synthetic considerations are also central to the development of 4-(2-Nitrobenzoyl)morpholine. Green chemistry approaches have been employed to minimize the ecological impact of its synthesis, aligning with the growing emphasis on sustainable pharmaceutical practices. This focus on eco-friendly methodologies reflects the broader trend in the industry toward responsible innovation.

Finally, the 4-(2-Nitrobenzoyl)morpholine molecule exemplifies the intersection of structural chemistry and biological function. Its unique architecture allows for the creation of diverse derivatives, each tailored to address specific therapeutic challenges. As research continues to uncover new applications, this compound is poised to play a significant role in the next generation of targeted therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)